ArticleInternational journal of clinical oncology2026
Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testing.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComprehensive genomic profiling (CGP) can detect multiple cancer-related genomic alterations, but real-world utility data in patients with thoracic malignancy is limited, especially in patients with non-small cell lung cancer (NSCLC) who have previously undergone single-plex or multi-plex gene testing. This study aimed to determine the detection rate of druggable cancer genomic alterations leading to treatment recommendations in these patients.
methodsThis study is a single-center retrospective study. We analyzed the CGP data in 70 patients with thoracic malignancies, including 53 NSCLC, at the Department of Chest Surgery, Fukushima Medical University Hospital.
resultsDruggable cancer genomic alterations were identified in 25% in patients with NSCLC (26% of all patients). Notably, CGP detected druggable cancer genomic alterations in 20% of patients with NSCLC with negative results in previous multi-plex gene testing and 47% of those with negative results in previous single-plex gene testing. Although CGP has clarified the mechanisms of resistance to TKIs, its clinical utility is currently limited. Liquid biopsy showed a low success rate in patients with metastases limited to the thoracic cavity or the central nervous system, but a high success rate in patients with extrathoracic lesions, especially those with bone metastases.
conclusionsCGP identified druggable cancer genomic alterations in patients with NSCLC even when prior single- or multi-plex gene testing had yielded negative results. Multi-plex gene testing may be preferable to CGP for patients with NSCLC who have only undergone single-plex gene testing. Even after multi-plex gene testing, druggable cancer genomic alterations may still be identified.
Indexed as
Identifiers
42384132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.